Interactions of cantharidin-like inhibitors with human protein phosphatase-5 in a Mg2+ system: molecular dynamics and quantum calculations
- 141 Downloads
The serine/threonine protein phosphatase type 5 (PP5) is a promising target for designing new antitumor drugs. This enzyme is a member of the PPP phosphatases gene family, which catalyzes a dephosphorylation reaction: a regulatory process in the signal transduction pathway that controls various biological processes. The aim of this work is to study and compare the inhibition of PP5 by ten cantharidin-like inhibitors in order to bring about contributions relevant to the better comprehension of their inhibitory activity. In this theoretical investigation, we used molecular dynamics techniques to understand the role of key interactions that occur in the protein active site; QM calculations were employed to study the interaction mode of these inhibitors in the enzyme. In addition, atoms in molecules (AIM) calculations were carried out to characterize the chemical bonds among the atoms involved and investigate the orbital interactions with their respective energy values. The obtained results suggest that the Arg275, Asn303, His304, His352, Arg400, His427, Glu428, Val429, Tyr451, and Phe446 residues favorably contribute to the interactions between inhibitors and PP5. However, the Asp271 and Asp244 amino acid residues do not favor such interactions for some inhibitors. Through the QM calculations, we can suggest that the reactional energy of the coordination mechanism of these inhibitors in the PP5 active site is quite important and is responsible for the inhibitory activity. The AIM technique employed in this work was essential to get a better comprehension of the transition states acquired from the mechanism simulation. This work offers insights of how cantharidin-like inhibitors interact with human PP5, potentially allowing the design of more specific and even less cytotoxic drugs for cancer treatments.
KeywordsSerine/threonine phosphatase 5 Cantharidin-like inhibitors Molecular dynamics QM/MM AIM
The authors wish to thank the Brazilian financial agencies Coordenação de Aperfeiçoamento Pessoal de Nível Superior/Ministério da Defesa (CAPES/MD), Conselho Nacional de Desenvolvimento Científico e Tecnológico (CNPq), Fundação de Amparo ao Ensino e Pesquisa de Minas Gerais (FAPEMIG), and Federal Univesity of Lavras (UFLA) for providing the physical infrastructure and working space. This work was also supported by Excellence project FIM.
- 4.Lajarín-Cuesta R, Arribas RL, De Los Ríos C (2016) Ligands for Ser/Thr phosphoprotein phosphatases: a patent review (2005-2015). Expert Opin Ther Pat 3776:1–19Google Scholar
- 12.Chattopadhyay D, Swingle MR, Salter EA, Wood E, D’Arcy B, Zivanov C, Abney K, Musiyenko A, Rusin SF, Kettenbach A, Yet L, Schroeder CE, Golden JE, Dunham WH, Gingras AC, Banerjee S, Forbes D, Wierzbicki A, Honkanen RE (2016) Crystal structures and mutagenesis of PPP-family ser/thr protein phosphatases elucidate the selectivity of cantharidin and novel norcantharidin-based inhibitors of PP5C. Biochem Pharmacol 109:14–26CrossRefGoogle Scholar
- 16.Ramalho TC,Castro AA, Silva DR, Silva MC, França TCC, Bennion BJ, Kuca K (2016) Computational enzymology and organophosphorus degrading enzymes: promising approaches toward remediation technologies of warfare agents and pesticides. Curr Med Chem 23:1041–1061Google Scholar
- 20.Accelrys Software (2012) Discovery studio modeling environment. http://accelrys.com/
- 21.Páll S, Abraham MJ, Kutzner C, Hess B, Lindahl E (2015) Tackling exascale software challenges in molecular dynamics simulations with GROMACS. In: Markidis S, Laure E (Eds.) Solving software challenges exascale. Int conf exascale appl software, EASC 2014 Stock Sweden April 2–3, revised selected papers. Springer, Cham pp 3–27Google Scholar
- 27.OriginLab Corporation (2018) Origin 8. OriginLab Corporation, NorthamptonGoogle Scholar
- 29.Frisch WCMJ, Trucks GW, Schlegel HB, Scuseria GE, Robb MA, Cheeseman JR, Scalmani G, Barone V, Petersson GA, Nakatsuji H, Li X, Caricato M, Marenich A, Bloino J, Janesko BG, Gomperts R, Mennucci B, Hratchian HP, Ort JV (2009) Gaussian Inc., WallingfordGoogle Scholar
- 33.Giacoppo JOS, França TCC, Kuča K, Da Cunha EFF, Abagyan R, Mancini DT, Ramalho TC (2014) Molecular modeling and in vitro reactivation study between the oxime BI-6 and acetylcholinesterase inhibited by different nerve agents. J Biomol Struct Dyn 33:2048–58Google Scholar